Twist Bioscience Collaborates with Deep Learning Experts deepCDR on Antibody Library Design
Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with deepCDR, focused on advanced antibody discovery using deep learning algorithms. This partnership aims to enhance Twist's ability to generate large panels of fully human antibody sequences, utilizing new AI Hypermutated scFv libraries. The collaboration is expected to streamline preclinical development by reducing validation work. Twist's innovative silicon platform enables the manufacturing of high-quality synthetic DNA, which is crucial for various applications, including drug discovery and genomics.
- Collaboration with deepCDR enhances antibody discovery capabilities using deep learning.
- Development of new AI Hypermutated scFv libraries may increase product offerings.
- Partnership expected to reduce downstream validation work in preclinical development.
- None.
“We continue to leverage and integrate cutting-edge technologies that advance our antibody discovery and optimization capabilities, and deepCDR offers a unique approach enabled by deep learning to generate large panels of fully human antibody sequences. Utilizing these sequences, we’ve built multiple fully human naïve synthetic antibody libraries – specifically AI Hypermutated single-chain fragment variable (scFv) library and a new coronavirus specific scFv library – to add to our ever-growing
“Twist has deep and broad expertise in designing and synthesizing very large antibody libraries as well as optimizing potential antibodies to improve their biochemical properties. We then apply our deep learning algorithms to decrease the downstream validation work necessary for preclinical development. It’s a productive and complementary collaboration for both organizations,” commented
About deepCDR Biologics (
deepCDR uses unique deep learning methods combined with its proprietary mammalian display platform to select from a massively wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles.
About
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including the ability of the collaboration with deepCDR to reduce downstream preclinical development validation work related to antibodies, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005236/en/
For
SVP, Corporate Affairs
925- 202-6211
media@twistbioscience.com
For deepCDR:
Director of R&D
info@deepcdr.com
Source:
FAQ
What is the recent collaboration announced by Twist Bioscience?
How does the collaboration with deepCDR benefit Twist Bioscience?
What technology does Twist Bioscience use for manufacturing synthetic DNA?